Nimill

2nd line treatment of acute pain & primary dysmenorrhoea, after failed treatment w/ at least 1 NSAID.

Adult 100 mg bd. Max duration of treatment: 15 days. Max single dose: 100 mg.

Should be taken with food.

Hypersensitivity to nimesulide, ASA or other NSAIDs. GI hemorrhage in progress or active gastroduodenal ulcer. Asthma. Patients w/ history of presence of hepatic disease. Patients who have demonstrated allergic-type reaction to sulfonamides. Patients w/ severe heart failure. Treatment of peri-operative pain in CABG surgery setting. History of GI bleeding or perforation, related to previous NSAIDs therapy. Active, or history of recurrent peptic ulcer/haemorrhage. Severe renal impairment. Moderate or severe hepatic impairment. 3rd trimester of pregnancy. Childn <12 yr.

Use at the lowest effective dose for the shortest possible time. Do not use for lowering fever. Risk of water retention; vision disorders; liver toxicity. Associated w/ serious liver injury in rare cases. Increased risk of serious CV thrombotic events, MI, & stroke; serious GI adverse events including bleeding, ulceration, & perforation of the stomach or intestines. Risk of renal papillary necrosis & other renal injury w/ long-term administration. Risk of renal toxicity in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. Not recommended in patients w/ advanced renal disease. Do not concomitantly use w/ other medicines that can also cause liver damage or in patients whose liver is already damaged. Caution in patients w/ history of hemorrhages, w/ upper GIT diseases & in those treated w/ anticoagulants or platelet aggregation inhibitors; hypertensive patients & those affected by reduced heart function; patients who require particular alertness if drowsiness or dizziness is observed during therapy. Do not administer to patients w/ severe renal failure. Risks of premature closure of the ductus arteriosus & potential to prolong parturition during the 3rd trimester of pregnancy. Caution during the 1st & 2nd trimesters of pregnancy, particularly from middle to end of 2nd trimester (onset at approx 20 wk) due to possible fetal renal dysfunction leading to oligohydramnios &, in some cases, neonatal renal impairment or failure. Administration during lactation is not advised. Caution when administering to elderly patients.

Pyrosis, nausea, gastralgia; erythematous or urticarioid skin rashes; headache, dizziness, drowsiness.

Potential interaction w/ anticoagulants or platelet aggregation inhibitors.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AX17 - nimesulide ; Belongs to the class of other non-steroidal antiinflammatory and antirheumatic products.

P₁S₁S₃